The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1744
December 22, 2025
View Complete Issue         Table of Contents 2019 
A Dihydroergotamine Autoinjector (Brekiya) for Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Dihydroergotamine Autoinjector (Brekiya) for Migraine
December 22, 2025 (Issue: 1744)
The FDA has approved Brekiya (Amneal), the first dihydroergotamine (DHE) autoinjector product. DHE has been available for IV, IM, SC and intranasal administration (Trudhesa, and others). Like other parenteral DHE products, Brekiya is indicated...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Dihydroergotamine Autoinjector (Brekiya) for Migraine
Article code: 1744c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.